BioScrip (NASDAQ:BIOS) updated its FY 2018 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $-0.32–0.26 for the period, compared to the Thomson Reuters consensus estimate of $-0.35. The company issued revenue guidance of $710-720 million, compared to the consensus revenue estimate of $697.28 million.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded BioScrip from a hold rating to a buy rating and set a $3.50 target price on the stock in a report on Wednesday, July 11th. BidaskClub downgraded BioScrip from a strong-buy rating to a buy rating in a report on Saturday, October 6th. Finally, Barrington Research reiterated a buy rating and issued a $4.00 target price on shares of BioScrip in a report on Wednesday, August 8th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $3.56.
Shares of NASDAQ BIOS traded up $0.05 during trading hours on Wednesday, hitting $3.26. The stock had a trading volume of 931,885 shares, compared to its average volume of 647,790. The stock has a market cap of $361.09 million, a price-to-earnings ratio of -7.41 and a beta of 0.42. BioScrip has a 52 week low of $1.93 and a 52 week high of $3.36.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The company had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. The business’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) earnings per share. Analysts predict that BioScrip will post -0.33 EPS for the current fiscal year.
WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/07/bioscrip-bios-releases-fy-2018-earnings-guidance.html.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Article: The risks of owning bonds
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.